Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 9—September 2024
CME ACTIVITY - Research

Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1

Viivi NevanlinnaComments to Author , Janne Aittoniemi, Reetta Huttunen, Tiina Luukkaala, and Sari Rantala
Author affiliations: Tampere University, Tampere, Finland (V. Nevanlinna, R. Huttunen, T. Luukkaala, S. Rantala); Tampere University Hospital, Tampere (V. Nevanlinna, R. Huttunen, T. Luukkaala, S. Rantala); Fimlab Laboratories, Tampere (J. Aittoniemi)

Main Article

Table 1

Clinical manifestations and disease severity in patients with Streptococcus dysgalactiae subspecies equisimilis bacteremia during November 2015–November 2019, Finland*

Infection type† Nonsevere disease, n = 142 Severe disease, n = 17 p value
Skin/soft tissue infection 107 (75) 10 (59) 0.154
Cellulitis 103 (73) 7 (41) 0.008
Purulent skin infection 27 (19) 4 (24) 0.746
Necrotizing fasciitis
1 (1)
3 (18)
0.004
Deep abscess 13 (9) 2 (12) 0.664
Bursitis
2 (1)
0
NA
Bone and joint infection 16 (11) 2 (12) 1.000
Osteomyelitis, all 7 (5) 1 (6) 1.000
Spondylitis 7 (5) 1 (6) 1.000
Arthritis, all 10 (7) 2 (12) 0.620
Periprosthetic joint infection
6 (4)
0
NA
Pneumonia 19 (13) 5 (29) 0.141
Empyema
1 (1)
0
NA
Endocarditis 5 (4) 0 NA
Aortitis 0 1 (6) NA
Foreign body infection 3 (2) 0 NA
Puerperal sepsis 4 (3) 0 NA
Intraabdominal infection 2 (1) 0 NA
Endophthalmitis 2 (1) 0 NA
Bacteremia without defined focus 14 (10) 3 (18) 0.397

*Values are no. (%) except as indicated. Severe disease was defined as treatment in the intensive care unit or death within 30 days after hospital admission. NA, not applicable. †One patient might have >1 clinical manifestations.

Main Article

1Preliminary results from this study were presented at the European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2024; Barcelona, Spain.

Page created: July 02, 2024
Page updated: August 22, 2024
Page reviewed: August 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external